ASMB ASSEMBLY BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1426800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.2%
TTM net income YoY71.2%
TTM EPS YoY116.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-31.8%
Net margin-16.6%
FCF margin-60.7%
EBITDA margin-31.7%
Returns
ROE-4.6%
ROA-3.9%
ROIC (approx.)-7.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets8.1%
Debt / equity0.00x
Current ratio12.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.65x
Accruals ratio10.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.96M | $13.37M | $8.21M | $42.47M | $10.79M | $9.63M | $9.42M | $7.36M |
| R&D expense | $20.23M | $14.92M | $14.90M | $17.25M | $16.59M | $16.12M | $14.85M | $14.28M |
| SG&A expense | $6.14M | $4.80M | $4.68M | $5.42M | $5.08M | $4.59M | $4.51M | $4.61M |
| Operating income | -$23.41M | -$6.34M | -$11.37M | $19.80M | -$10.88M | -$11.09M | -$9.94M | -$11.53M |
| Pretax income | — | — | — | $22.09M | -$9.20M | -$10.20M | — | -$10.41M |
| Income tax | — | — | — | $0 | $0 | $0 | — | -$76,000 |
| Net income | -$20.26M | -$3.86M | -$9.08M | $22.09M | -$9.20M | -$10.20M | -$8.82M | -$10.34M |
| EBITDA | -$23.39M | -$6.32M | -$11.34M | $19.83M | -$10.85M | -$11.06M | -$9.91M | -$11.50M |
| EPS (basic) | -0.93 | -0.20 | -0.54 | — | -0.72 | -1.33 | -1.17 | — |
| EPS (diluted) | -0.93 | -0.20 | -0.54 | — | -0.72 | -1.33 | -1.17 | — |
| Weighted avg. shares (diluted) | 21.78M | 18.85M | 16.90M | — | 12.69M | 7.66M | 7.51M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.07M | $32.29M | $31.12M | $58.45M | $22.53M | $24.01M | $23.41M | $38.34M |
| Short-term investments | $285.19M | $288.07M | $195.48M | $189.66M | $210.02M | $50.97M | $67.61M | $73.73M |
| Receivables | $582,000 | $822,000 | $451,000 | $974,000 | $912,000 | — | — | $0 |
| Current assets | $321.16M | $327.98M | $232.61M | $254.55M | $236.81M | $77.47M | $95.53M | $115.50M |
| PP&E, net | $291,000 | $315,000 | $214,000 | $221,000 | $229,000 | $219,000 | $251,000 | $284,000 |
| Total assets | $325.29M | $330.83M | $235.51M | $257.59M | $240.00M | $80.78M | $99.02M | $119.17M |
| Current liabilities | $24.92M | $23.45M | $35.00M | $48.78M | $53.38M | $47.29M | $46.63M | $47.80M |
| Total liabilities | $26.49M | $25.18M | $36.90M | $50.84M | $57.30M | $62.68M | $71.88M | $85.81M |
| Shareholders' equity | $298.79M | $305.65M | $198.61M | $206.75M | $182.69M | $18.10M | $27.13M | $33.36M |
| Shares outstanding | 20.37M | 19.85M | 15.89M | 15.86M | 15.82M | 7.67M | 7.62M | 7.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.16M | -$15.49M | -$22.10M | $14.24M | -$15.13M | -$16.76M | -$23.44M | -$407,000 |
| Capital expenditure | $121,000 | $0 | $19,000 | $24,000 | $42,000 | $0 | $0 | $0 |
| Free cash flow | -$17.29M | -$15.49M | -$22.12M | $14.21M | -$15.18M | -$16.76M | -$23.44M | -$407,000 |
| Investing cash flow | $3.51M | -$92.08M | -$5.38M | $21.22M | -$158.27M | $16.99M | $6.59M | -$6.70M |
| Financing cash flow | $10.44M | $108.73M | $149,000 | $456,000 | $171.93M | $357,000 | $1.92M | $17.00M |
| Depreciation & amortization | $24,000 | $20,000 | $26,000 | $32,000 | $32,000 | $32,000 | $33,000 | $32,000 |
| Stock-based compensation | $3.32M | $2.42M | $1.12M | $1.46M | $1.67M | $834,000 | $712,000 | $751,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.